QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:FBIO

Fortress Biotech (FBIO) Stock Forecast, Price & News

$0.28
-0.02 (-6.59%)
(As of 09/26/2023 ET)
Compare
Today's Range
$0.28
$0.31
50-Day Range
$0.28
$0.65
52-Week Range
$0.28
$1.16
Volume
411,687 shs
Average Volume
615,632 shs
Market Capitalization
$37.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Fortress Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,664.9% Upside
$5.00 Price Target
Short Interest
Healthy
0.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Fortress Biotech in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$117,500 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.92) to ($0.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

318th out of 964 stocks

Pharmaceutical Preparations Industry

130th out of 445 stocks


FBIO stock logo

About Fortress Biotech (NASDAQ:FBIO) Stock

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

FBIO Price History

FBIO Stock News Headlines

Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
See More Headlines
Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

FBIO Company Calendar

Last Earnings
8/14/2023
Today
9/26/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:FBIO
CUSIP
21976U10
Employees
187
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+1,575.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-86,570,000.00
Net Margins
-152.63%
Pretax Margin
-357.79%

Debt

Sales & Book Value

Annual Sales
$75.74 million
Book Value
$0.45 per share

Miscellaneous

Free Float
97,287,000
Market Cap
$39.71 million
Optionable
Optionable
Beta
2.10
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Lindsay Allan Rosenwald (Age 68)
    Exec. Chairman, Pres & CEO
    Comp: $942.78k
  • Mr. Michael S. Weiss Esq. (Age 57)
    Vice Chairman & Exec. Vice Chairman of Strategic Devel.
    Comp: $167.92k
  • Mr. David Jin (Age 32)
    CFO & Head of Corp. Devel.
    Comp: $976.96k
  • Dr. George C. Avgerinos (Age 69)
    Sr. VP of Biologics Operations
    Comp: $386.49k
  • Mr. Samuel Berry
    Gen. Counsel & Corp. Sec.













FBIO Stock - Frequently Asked Questions

Should I buy or sell Fortress Biotech stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FBIO shares.
View FBIO analyst ratings
or view top-rated stocks.

What is Fortress Biotech's stock price forecast for 2023?

3 equities research analysts have issued 1 year price targets for Fortress Biotech's stock. Their FBIO share price forecasts range from $5.00 to $5.00. On average, they predict the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 1,575.6% from the stock's current price.
View analysts price targets for FBIO
or view top-rated stocks among Wall Street analysts.

How have FBIO shares performed in 2023?

Fortress Biotech's stock was trading at $0.6550 at the beginning of 2023. Since then, FBIO shares have decreased by 54.4% and is now trading at $0.2984.
View the best growth stocks for 2023 here
.

Are investors shorting Fortress Biotech?

Fortress Biotech saw a increase in short interest in August. As of August 31st, there was short interest totaling 710,900 shares, an increase of 24.1% from the August 15th total of 572,800 shares. Based on an average daily volume of 621,500 shares, the days-to-cover ratio is currently 1.1 days. Currently, 0.8% of the company's stock are short sold.
View Fortress Biotech's Short Interest
.

When is Fortress Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our FBIO earnings forecast
.

How were Fortress Biotech's earnings last quarter?

Fortress Biotech, Inc. (NASDAQ:FBIO) announced its quarterly earnings results on Monday, August, 14th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.02. The biopharmaceutical company earned $17.39 million during the quarter, compared to analysts' expectations of $13.28 million. Fortress Biotech had a negative net margin of 152.63% and a negative trailing twelve-month return on equity of 246.79%.

What other stocks do shareholders of Fortress Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX).

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

Who are Fortress Biotech's major shareholders?

Fortress Biotech's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (0.91%), Acadian Asset Management LLC (0.80%), Geode Capital Management LLC (0.64%), 1900 Wealth Management LLC (0.30%), Renaissance Technologies LLC (0.17%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Eric K Rowinsky and Lindsay A Md Rosenwald.
View institutional ownership trends
.

How do I buy shares of Fortress Biotech?

Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fortress Biotech's stock price today?

One share of FBIO stock can currently be purchased for approximately $0.30.

How much money does Fortress Biotech make?

Fortress Biotech (NASDAQ:FBIO) has a market capitalization of $39.71 million and generates $75.74 million in revenue each year. The biopharmaceutical company earns $-86,570,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.

How many employees does Fortress Biotech have?

The company employs 187 workers across the globe.

How can I contact Fortress Biotech?

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.fortressbiotech.com. The biopharmaceutical company can be reached via phone at (781) 652-4500, via email at ir@fortressbiotech.com, or via fax at 781-652-4545.

This page (NASDAQ:FBIO) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -